[1]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169-170.[doi:10.3969/j.issn.1006-1959.2019.23.054]
　LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Medical Information,2019,32(23):169-170.[doi:10.3969/j.issn.1006-1959.2019.23.054]
点击复制

GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年23期
页码:
169-170
栏目:
诊疗技术
出版日期:
2019-12-01

文章信息/Info

Title:
Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma
文章编号:
1006-1959（2019）23-0169-02
作者:
刘 冰1; 杨 帅1; 费锡斌1; 宋 健2
（1.天津市宝坻区人民医院生化科，天津 301800；2.天津市中心妇产科医院免疫科，天津 301800）
Author(s):
LIU Bing1; YANG Shuai1; FEI Xi-bin1; SONG Jian2
(1.Department of Biochemistry,Baodi District People’s Hospital,Tianjin 301800,China;2.Department of Immunology,Tianjin Central Hospital of Obstetrics and Gynecology,Tianjin 301800, China)
关键词:
肝细胞癌; 磷脂酰肌醇蛋白多糖-3; 细胞角蛋白-19
Keywords:
Hepatocellular carcinoma; Phosphatidylinositol-3; Cytokeratin-19
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2019.23.054
文献标志码:
A
摘要:
目的 研究磷脂酰肌醇蛋白多糖-3（GPC-3）联合细胞角蛋白-19（CK-19）免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用价值。方法 选择2017年1月~2019年1月我院通过肝穿刺或外科手术获取的肝癌标本91例。所有标本按照GPC-3及CK-19检测流程处理，比较肝细胞癌（HCC）、肝内胆管细胞癌（ICC）及肝细胞癌合并肝内胆管细胞癌（CHC）标本中GPC-3及CK-19检测阳性率，及不同分化程度HCC的GPC-3及CK-19阳性率。结果 HCC与CHC中GPC-3阳性率高于ICC，ICC与CHC中CK-19阳性率高于HCC，差异有统计学意义（P＜0.05）；中、低分化的HCC标本中GPC-3、CK-19阳性率高于高分化HCC，差异有统计学意义（P＜0.05）。结论 在肝细胞癌诊断及鉴别诊断中采取GPC-3联合CK-19免疫组化检测，可有效检出HCC，并可与CHC及ICC进行区分，在早期诊断中也具有一定应用价值。
Abstract:
Objective To study the application value of phosphatidylinositol-3 (GPC-3) combined with cytokeratin-19 (CK-19) immunohistochemistry in the diagnosis and differential diagnosis of hepatocellular carcinoma. Methods From January 2017 to January 2019, 91 cases of liver cancer specimens obtained by liver puncture or surgery in our hospital were selected.All specimens were processed according to the GPC-3 and CK-19 test procedures to compare hepatocellular carcinoma (HCC),Positive rate of GPC-3 and CK-19 in intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma combined with intrahepatic cholangiocarcinoma (CHC) specimens,and the positive rate of GPC-3 and CK-19 of different degrees of differentiation HCC.Results The positive rate of GPC-3 and CK-19 in HCC and CHC was higher than that in ICC, the difference was statistically significant (P<0.05). The positive rate of GPC-3 in medium and poorly differentiated HCC specimens was higher than that in well differentiated HCC. The positive rate of CK-19 in medium and poorly differentiated HCC specimens was higher than that in well differentiated HCC,the difference was statistically significant (P<0.05). Conclusion GPC-3 combined with CK-19 immunohistochemistry in the diagnosis and differential diagnosis of hepatocellular carcinoma can effectively detect HCC and distinguish it from CHC and ICC, and it has certain application value in early diagnosis.

参考文献/References:

[1]温实,戴新武,黄丽娟,等.KR1B10与GPC-3免疫组化检测对肝细胞肝癌的诊断价值[J].现代生物医学进展,2015,15(32):6263-6265.[2]刘冲,唐浩,邓霖,等.血清miRNA-186,miRNA-30c在肝细胞性癌中诊断价值的研究[J].现代检验医学杂志,2016,31(6):44-47.[3]周新刚,张亮,王鹏,等.Arginase-1联合Glypican-3在肝细胞肝癌和非肝脏来源肿瘤鉴别诊断中的意义[J].临床与实验病理学杂志,2017,33(8):841-846.[4]晏文强,谢明水,刘杨.GP73、AFP-L3与GPC-3联合检测在原发性肝癌诊断中的临床价值[J].中国实验诊断学,2015,19(10):1651-1654.[5]王娟,张曙光,孙颖,等.免疫组化检测GPC-3与CK-19在肝细胞癌诊断中的应用价值[J].临床和实验医学杂志,2017,16(14):50-53.

相似文献/References:

[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及 肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
　WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Medical Information,2018,31(23):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
　LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Medical Information,2022,35(23):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[3]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
　PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Medical Information,2022,35(23):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[4]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
　LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Medical Information,2020,33(23):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[5]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
　PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Medical Information,2022,35(23):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
[6]杨孟涛,汪 艇,杜 伟,等.miR-181b-5p靶向调控SPP1在肝细胞癌中过表达的临床意义及作用机制[J].医学信息,2022,35(24):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
　YANG Meng-tao,WANG Ting,DU Wei,et al.Clinical Significance and Mechanism of miR-181b-5p Targeting to Regulate SPP1 Overexpression in Hepatocellular Carcinoma[J].Medical Information,2022,35(23):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
[7]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
　SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Medical Information,2021,34(23):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[8]唐 菀,张晓珣,柴 进.SLCO1B1在肝细胞癌中的表达及其对患者预后的影响[J].医学信息,2023,36(02):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
　TANG Wan,ZHANG Xiao-xun,CHAI Jin.Expression of SLCO1B1 in Hepatocellular Carcinoma and its Effect on Prognosis[J].Medical Information,2023,36(23):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
[9]蒙建源,朱刚健.应用细胞免疫治疗肝细胞癌的研究[J].医学信息,2023,36(05):177.[doi:10.3969/j.issn.1006-1959.2023.05.037]
　MENG Jian-yuan,ZHU Gang-jian.Study on Cellular Immunotherapy for Hepatocellular Carcinoma[J].Medical Information,2023,36(23):177.[doi:10.3969/j.issn.1006-1959.2023.05.037]
[10]张 政,卢鸿健,李明慧,等.基于生物信息学分析肝细胞癌中lncRNA-miRNA-mRNA的调控网络[J].医学信息,2023,36(06):1.[doi:10.3969/j.issn.1006-1959.2023.06.001]
　ZHANG Zheng,LU Hong-jian,LI Ming-hui,et al.Analysis of lncRNA-miRNA-mRNA Regulatory Network in Hepatocellular Carcinoma Based on Bioinformatics[J].Medical Information,2023,36(23):1.[doi:10.3969/j.issn.1006-1959.2023.06.001]

更新日期/Last Update: 2019-12-01